Patanjali Ayurved's research, published in the Journal of Inflammation Research, reveals promising results for their Ayurvedic treatment of psoriasis using Psorogrit tablets and Divya Taila.

“We found that low-grade systemic inflammation, measured as SII, NLR, and CRP, is an independent risk factor for psoriasis, especially moderate to severe disease,” authors of the study concluded.

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

When categorizing the severity of psoriasis, it’s generally defined by the total amount of skin surface area covered by plaques. Less than 3% is considered mild, 3-10% moderate, and anything ...

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...

A clinical diagnosis was made of psoriasis and he was prescribed clobetasol propionate ointment with salicylic acid 6% in petrolatum that should be applied in the evening to his elbows and knees ...

Hypocalcemia, or low levels of calcium in the blood, can lead to calcium deficiency symptoms such as muscle aches and fatigue. To boost calcium levels, a doctor may recommend eating more calcium ...

The U.S. dermatology market is at a financial crossroads. With a projected growth from $40.55 billion in 2023 to over $70 billion by 2030, the increasing prevalence of psoriasis and the accompanying ...

In a major milestone for Patanjali, its research on Ayurvedic cure for psoriasis has been published in the internationally acclaimed Journal of Inflammation Research, a Taylor & Francis publication.

Patanjali Ayurved has achieved another milestone that could lead to a major breakthrough in the treatment of 'psoriasis', a severe skin ailment. The company said that its research on this disease has ...

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study. The randomized, ...